Research / Scientific departments / Immunology / Publications



X. ZHANG, A. LEPELLEY, E. AZRIA, P. LEBON, G. ROGUET, O. SCHWARTZ, O. LAUNAY, C. LECLERC, R. LO-MAN. Neonatal Plasmacytoid Dendritic Cells (pDCs) Display Subset Variation but Can Elicit Potent Anti-Viral Innate Responses. PLOS One, 10 Jan 2013 | 10.1371/journal.pone.0052003


C. GUILLEREY, J. MOURIES, G. POLO, N. DOYEN, H.K.W LAW, S. CHAN, P. KASTNER, C. LECLERC AND DADAGLIO G. Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice. Blood, 2012, 120, 90-99.
F. SAYES, L. SUN, M. DI LUCA, R. SIMEONE, N. DEGAIFFIER, L. FIETTE, S. ESIN, R. BROSCH, D. BOTTAI, C. LECLERC and MAJLESSI L.Strong Immunogenicity and Cross-Reactivity of Mycobacterium tuberculosis ESX-5 Type VII Secretion -Encoded PE-PPE Proteins Predicts Vaccine Potential. Cell Host & Microbe, 2012,11, 352–363.
R. FISER, J. MASIN, L. BUMBA, E. POSPISILOVA, C. FAYOLLE, M. BASLER, L. SADILKOVA, I. ADKINS, J. KAMANOVA, J. CERNY, I. KONOPASEK, R. OSICKA, C. LECLERC and P. SEBO. Calcium influx rescues adenylate cyclase-hemolysin from rapid cell membrane removal and enables phagocyte permeabilization by toxin pores. PLoS Pathogens, 2012, 8:e1002580.
SAINZ-PEREZ, A., A. LIM, B. LEMERCIER and C. LECLERC. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed towards public sequences. Cancer Res. 2012, 72, 3557-3569.
H. DONG, O. STANEK, RUDILLA-SALVADOR, F., U. LANGËR, E. MORILLON, C. UNG, P. SEBO*, C. LECLERC and L. MAJLESSI. Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX Antigen into airway dendritic cells Mucosal Immunology, 2012 Oct 3. doi: 10.1038/mi.2012.92.
BOTTAI, D., M. DI LUCA, L. MAJLESSI, W. FRIGUI, R. SIMEONE, F. SAYES, W. BITTER, M.J. BRENNAN, C. LECLERC, G. BATONI, M. CAMPA, R. BROSCH, and S. ESIN. 2012. Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol Microbiol 83:1195-1209.
RUDILLA, F., C. FAYOLLE, N. CASARES, M. DURANTEZ, L. ARRIBILLAGA, T. LOZANO, L. VILLANUEVA, R. PIO, P. SAROBE, C. LECLERC, J. PRIETO and J.J. LASARTE. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine. 2012, 30, 2848-2858.
STANEK, O., I. LINHARTOVA, L. MAJLESSI, C. LECLERC and P. SEBO. Complexes of Streptavidin-Fused Antigens with Biotinylated Antibodies Targeting Receptors on Dendritic Cell Surface: A Novel Tool for Induction of Specific T-Cell Immune Responses. Mol Biotechnol. 2012, 51, 221-232.


D. Bottai, L. Majlessi, R. Simeone, W. Frigui, C. Laurent, P. Lenormand, J. Chen, I. Rosenkrands, M. Huerre, C. Leclerc, S.T. Cole and Brosch R. ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis. J. Infect. Dis, 2011, 203, 1155-64.
T. Freire, R. Lo-Man, S. Bay, and C. Leclerc. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17 biased T cell responses. J Biol Chem., 2011, 286, 7797-811.
A. OLIVIER, A. SAINZ-PEREZ, H. DONG, T. SPARWASSER, L. MAJLESSI and C. LECLERC. The adjuvant effect of TLR agonists on CD4+ effector T cells is under the indirect control of regulatory T cells. Eur J Immunol., 2011, 41, 2303-2313.
L. MASCARELL, N. SAINT-LU, H. MOUSSU, A. ZIMMER, Y-C LONE, D. LADANT, C. LECLERC, S. TOURDOT, L. VEN OVERTVELT and P. MOINGEON. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol., 2011, 4, 638-47.


T. FREIRE, X.M. ZHANG, E. DERIAUD, C. GANNEAU, S. VIGHIER-GUERRE, R. LO-MAN, S. BAY and C. LECLERC. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood, 2010, 116, 3526-3536.
C. LECLERC, R. OSICKA and P. SEBO. Adenylate cyclase toxin translocates across target cell membrane without forming a pore. Molecular Microbiology, 2010, 75, 1550-1562
C. FAYOLLE, M. DAVI, H. DONG, D. RITZEL, A. LE PAGE, F. KNIPPING, L. MAJLESSI, D. LADANTand C. LECLERC. Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope. Vaccine, 2010, 28, 6930-6941.
M. DURANTEZ, C. FAYOLLE, N. CASARES, V. BELSUE, J. IGNACIO RIEZU, P. SAROBE, J. PRIETO, F. BORRAS-CUESTA, C. LECLERC and J.J. LASARTE. Tumor therapy in mice by tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine, 2010, 28, 7146-7154.
C. Leclerc. Towards a rational approach to vaccine development. Hum Vaccin, 2010, 6, 292-296.
A. Osickova, J. Masin, C. Fayolle, J. Krusek, M. Basler, E. Pospisilova, C. Leclerc, R. Osicka and P. Sebo. Adenylate cyclase toxin translocates across target cell membrane without forming a pore. Mol Microbiol., 2010, 75, 1550-1562.


X. ZHANG, L. MAJLESSI, E. DERIAUD, C. LECLERC and R. LO-MAN. Co-activation of Syk and MyD88 pathways by bacteria promotes regulatory properties of neutrophils. Immunity, 2009, 31, 761-771.
M. TERME, G. MIGNOT, E. ULLRICH, M. BONMORT, V. MINARD-COLIN, A. JACQUET, J.L. SCHULTZE, G. KROEMER, C. LECLERC, N. CHAPUT, L. ZITVOGEL. The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. Cancer. Res., 2009, 69, 6590-6597.
E. BADELL, F. NICOLLE, S. CLARK, L. MAJLESSI, F. BOUDOU, A. MARTINO, L. CASTELLO-BRANCO, C. LECLERC, D.J. LEWIS, P.D. MARSH, B. GICQUEL and N. WINTER. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine, 2009, 27, 28-37.
BAY, S. FORT, L. BIRIKAKI, C. GANNEAU, E. SAMAIN, Y.M. COÏC, F. BONHOMME, E. DERIAUD, C. LECLERC, and R. LO-MAN. Induction of a melanoma-specific antibody response by a monovalent, but not a divalent, synthetic GM2 neoglycopeptide. Chem. Med. Chem., 2009, 4, 582-587.


J. MOURIES, G. MORON, G. SCHLECHT, N. ESCRIOU, G. DADAGLIO and C. LECLERC. Plasmacytoid dendritric cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood, 2008, 112, 3713-3722.
W. FRIGUI, D. BOTTAI, L. MAJLESSI, M. MONOT, E. JOSSELIN, P. BRODIN, T. GARNIER, B. GICQUEL, C. MARTIN, C. LECLERC, S. COLE and R. BROSCH. Control of M. tuberculosis ESAT-6 secretion and specific T-cell recognition by PhoP. PLoS Pathogens, 2008, 4, e33.
B. JARON, E. MARANGHI, C. LECLERC and L. MAJLESSI . Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS One, 2008, 3, e2833.
G. DORE, C. LECLERC and F. LAZARINI. Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions. J. Neuroimmunol., 2008, 197, 74-80.
C. LECLERC, C. BROSE, C. NOUZE, F. LEONARD, L. MAJLESSI, S. BECKER, H. VON BRIESEN and R. LO-MAN. Immobilized cytokines as biomaterials for manufacturing immune cell based vaccines. J. Biomed. Mater. Res. A., 2008, 86, 1033-1040.


X. ZHANG, E. DERIAUD, X. JIAO, D. BRAUN, C. LECLERC and R. LO-MAN. Type I interferons cooperate with regulatory B cells to protect neonates from acute inflammation. J. Exp. Med., 2007, 204, 1107-1118.
S. HERVAS-STUBBS, F. BOISGERAULT, N. THIEBLEMONT and C. LECLERC. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood, 2007, 109, 5318-5326.
P. BERRAONDO, C. NOUZE, X. PREVILLE, D. LADANT and C. LECLERC. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive and regulatory components of the immune system. Cancer Research, 2007, 67, 8847-8855.
J.J. LASARTE, N. CASARES, M. GORRAIZ, S. HERVAS-STUBBS, L. ARRIBILLAGA, C. MANSILLA, D. LLOPIZ, P. SAROBE, F. BORRAS-CUESTA, J. PRIETO and C. LECLERC. The Extra Domain A from fibronectin targets antigens to Toll like receptor 4 expressing cells and induces cytotoxic T cell responses in vivo. J. Immunol., 2007, 178, 748-756.
S. HERVAS-STUBBS, P. RUEDA, L. LOPEZ and C. LECLERC. Insect baculovirus strongly potentiate adaptive immune responses through the induction of type 1 interferon. J. Immunol. 2007, 178, 2361-2369.
L. MAJLESSI, B. COMBALUZIER, I. ALBRECHT, J.E. GARCIA, C. NOUZE, J. PIETERS and C. LECLERC. Inhibition of phagosome maturation by Mycobacteria does not interfere with presentation of mycobacterial antigens by MHC molecules. J. Immunol., 2007, 179, 1825-1833.
T.G. CONNELL, M.S. SHEY, R. SELDON, M.X. RANGAKA, G. VAN CUTSEM, M. SIMSOVA, Z. MARCEKOVA, P. SEBO, N. CURTIS, L. DIWAKAR, G.A. MEINTJES, C. LECLERC, R.J. WILKINSON and K.A. WILKINSON. Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in HIV infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector. Clinical and Vaccine Immunology, 2007, 14, 847-854.


J.Y. BERTRAND, G.E. DESANTI, R. LO-MAN, C. LECLERC, A. CUMANO and R. GOLUB. Fetal spleen stroma drives macrophage commitment. Development, 2006, 133, 3619-3628.
L. MAJLESSI, M.M. GABELLEC, A. MORIS, O. SCHWARTZ, J. DI SANTO, A. CUMANO, C. LECLERC AND F. LAZARINI. Processing of the bovine spondiform encephalopathy-specific prion protein by dendritic cells. J. Virol., 2006, 80, 4656-4663
P. BRODIN, L. MAJLESSI, L. MARSOLLIER, M.I. DE JONGE, D. BOTTAI, C. DEMANGEL, J. HINDS, O. NEYROLLES, P.D. BUTCHER, C. LECLERC, S. COLE and R. BROSCH. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Inf. Immunity, 2006, 74, 88-98.
C. BAUCHE, C. NOUZE, D. LADANT, S.T. COLE, P. SEBO and C. LECLERC. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Inf. Immunity, 2006, 74, 2128-2137.
M.J. ROJAS, C. NOUZE, P. BRODIN, P. SEBO and C. LECLERC. High frequency of CD4+ T-cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Inf. Immunity, 2006, 74, 3396-3407
T. FREIRE, R. LO-MAN, F. PILLER, V. PILLER, C. LECLERC and S. BAY. Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for anti-tumor vaccination. Glycobiology, 2006, 16, 390-401.
G. SCHLECHT, J. MOURIES, M. POITRASSON-RIVIERE, C. LECLERC and G. DADAGLIO. Purification of splenic dendritic cells induces maturation and capacity to stimulate Th1 response in vivo. Int. Immunol., 2006, 18, 445-452.
L. MASCARELL, C. BAUCHE, C. FAYOLLE, O. M. DIOP, M. DUPUY, N. NOUGAREDE, R. PERRAULT, D. LADANT and C. LECLERC. Delivery of the HIV-1 TAT protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates. Vaccine, 2006, 24, 3490-3499.
T. FREIRE, S. BAY, S. VICHIER-GUERE, R. LO-MAN and C. LECLERC. Carbohydrate antigens : synthesis aspects and immunological applications in cancer. Mini-Review in Medicinal Chemistry, 2006, 6, 1357-1373.


C.M. SUN, E. DERIAUD, C. LECLERC and R. LO-MAN. Upon TLR9 signaling, B cells controls the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity, 2005, 22, 467-477.
X. PREVILLE, D. LADANT, B. TIMMERMAN and C. LECLERC. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Research, 2005, 65, 641-649.
F. BOISGERAULT, P. RUEDA, C.M. SUN, S. HERVAS-STUBBS, M. ROJAS and C. LECLERC. Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal. J. Immunol., 2005, 174, 3432-3439.
L. MAJLESSI, P. BRODIN, R. BROSCH, M.J. ROJAS, H. KHUN, M. HUERRE, S.T. COLE and C. LECLERC. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J. Immunol., 2005, 174, 3570-3579.
P. BRODIN, M.I. DE JONGE, L. MAJLESSI, C. LECLERC, M NILGES, S.T. COLE and R. BROSCH. Functional analysis of Early Secreted Antigenic Target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involced in secretion, complex formation, virulence and immunogenicity. J. Biol. Chem., 2005, 280, 33953-33959.
L. MASCARELL, C. FAYOLLE, C. BAUCHE, D. LADANT and C. LECLERC. Induction of neutralizing antibodies, Th1 polarized and CD4-independent CD8+ T-cell responses following the delivery of HIV-1 Tat protein by recombinant adenylate cyclase of Bordella pertussis. J. Virol., 2005, 179, 9872-9884.
J. MASIN, M. BASLER, O. KNAPP, M. EL-AZAMI-EL-IDRISSI, E. MAIER, I. KONOPASEK, R. BENZ, C. LECLERC and P. SEBO. Acylation of lysine 860 allows tight binding and cytotoxicity of Bordetella adenylate cyclase on CD11b-expressing cells. Biochemistry, 2005, 44, 12759-12766.
K.A. WILKINSON, M. SIMSOVA, E. SCHOLVINCK, P. SEBO, C. LECLERC, H.M. VORDERMEIER, S.J. DICKSON, R.N. DAVIDSON, G. PASVOL, M. LEVIN and R.J. WILKINSON. Efficient ex vivo restimulation of Mycobacterium tuberculosis- specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Inf. Immunity, 2005, 73, 2991-2998.
S. GRIGALEVICIUS, S. CHIERICI, O. RENAUDET, R. LO-MAN, E. DERIAUD, C. LECLERC and P. DUMY. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjugate Chemistry, 2005, 16, 1149-1159.
L. MAJLESSI and C. LECLERC. Immunological basis for the rational design of new vaccines. In : Vaccines. Frontiers in design and development. Edited by
B. Moingeon. Horizon Bioscience. 2005, 19-40.


B. ADKINS, C. LECLERC and S. MARSHALL-CLARKE. Neonatal adaptive immunity comes of age. Nature Rev. Immunol., 2004, 4, 553-564.
V.G. MORON, G. DADAGLIO and C. LECLERC. New tools for antigen delivery to the MHC class I pathway. Trends in Immunology, 2004, 25, 92-97.
G. SCHLECHT, S. GARCIA, N. ESCRIOU, A A. FREITAS, C. LECLERC and G. DADAGLIO. Murine plasmacytoid dendritic cells induce effector/memory CD8+T-cell responses in vivo after viral stimulation. Blood, 2004, 104, 1808-1815.
R. LO-MAN, S. VICHIER-GUERRE, R. PERRAUT, E. DERIAUD, V. HUTEAU, L. BENMOHAMED, O.M. DIOP, P.O. LIVINGSTON, S. BAY and C. LECLERC. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor specific antibodies in non-human primates. Cancer Research, 2004, 64, 4987-4994.
M. REGNER, X. MARTINEZ, E. BELNOUE, C.M. SUN, F. BOISGERAULT, P.H. LAMBERT, C. LECLERC and C.A. SIEGRIST. Partial activation of neonatal CD11c+ dendritic cells and induction of adult-like CD8+ cytotoxic T cell responses by synthetic microspheres.. J. Immunol., 2004, 173, 2669-2674.
G. SCHLECHT, J. LOUCKA, H. NAJAR, P. SEBO and C. LECLERC. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1 polarized T-cell priming. J. Immunol., 2004, 173, 6089-6097.
P. BRODIN, L. MAJLESSI, R. BROSCH, D. SMITH, G. BANCROFT, S. CLARCK, A. WILLIAMS, C. LECLERC and S.T. COLE. Enhanced protection against Tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against Region of Difference 1 Antigens. J. Infectious Diseases, 2004, 190, 115-122.
C. DEMANGEL, P. BRODIN, P. COCKLE, R. BROSCH, L. MAJLESSI, C. LECLERC and S.T. COLE. Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenecity independently of a 10-kilodalton culture filtrate protein and ESAT-6. Infect. Immun., 2004, 72, 2170-2176.
H.M. VORDERMEIER, M. SIMSOVA, R.J. WILKINSON, R.G. HEWINSON, P. SEBO and C. LECLERC. Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase (CyaA) by T cells from cattle with bovine tuberculosis. Inf. Immunity, 2004, 72, 6255-6261.
            M. SIMSOVA, P. SEBO and C. LECLERC. The adenylate cyclase toxin from Bordella pertussis – a novel promising vehicle for antigen delivery to dendritic cells. Int. J. Med. Microbiol., 2004, 293, 571-576


AS. PYM*, P. BRODIN*, L. majlessi*, r. brosch, c. demangel, a. williams, k.e.griffiths, g. marchal, C. LECLERC and S.T. COLE (* Equal contribution). Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Medecine, 2003, 9, 533-539.
C.M. SUN, L. FIETTE, M. TANGUY, C. LECLERC and R. LO-MAN. Ontogeny and innate properties of neonatal dendritic cells. Blood, 2003, 102, 585-589.
X. JIAO, R. LO-MAN, N. WINTER, E. DERIAUD, B. GICQUEL and C. LECLERC. The shift of Th1 to Th2 immunodominance associated with the chronicity of M. bovis BCG infection does not affect the memory response. J. Immunol, 2003, 170, 1392-1398.
V.G. MORON, P. RUEDA, C. SEDLIK and C. LECLERC. In vivo, dendritic cells cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol., 2003, 171, 2242-2250.
M. EL-AZAMI-EL-IDRISSI, C. BAUCHE, J. LOUCKA, R. OSICKA, P. SEBO, D. LADANT and C. LECLERC. Interaction of Bordetella adenylate cyclase with CD11b/CD18: Role of toxin acylation and identification of the main integrin interaction domain. J. Biol. Chem., 2003, 278, 38514-38521.
L. MAJLESSI, M.J. ROJAS, P. BRODIN and C. LECLERC. CD8+T-cell responses of mycobacteria-infected mice to a newly identified MHC-I-restricted epitope shared by proteins of ESAT-6 family. Inf. Immun., 2003, 71, 7173-7177.
G. DADAGLIO, S. MOREL, C. BAUCHE, Z. MOUKRIM, F.A. LEMONNIER, B.J. van den EYNDE, D. LADANT and C. LECLERC. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int. Immunol, 2003, 15, 1423-1430.
N. HAICHEUR, F. BENCHETRIT, E. BISMUTH, C. LECLERC, T. FALGUIERES, C. FAYOLLE, M. AMESSOU, W.H. FRIDMAN, L. JOHANNES AND E. TARTOUR. The B-subunit of Shiga toxin coupled to full size antigenic protein elicits humoral and cellular immune responses associated with a TH1 dominant polarization. Int. Immunol., 2003, 15, 1161-1171.
C. LECLERC. New approaches in vaccine development. Comp. Immun. Microbiol. Infect. Dis., 2003, 26, 329-341.


G. MORON, P. RUEDA, I. CASAL and C. LECLERC. CD8a- CD11b+ dendritic cells present exogenous virus-like particles (VLPs) to CD8+ T cells and subsequently express CD8a and DEC205 molecules J. Exp. Med. 2002, 195, 1233-1245.
X. JIAO*, R. LO-MAN*, P. GUERMONPREZ, L. FIETTE, E. DERIAUD, S. BURGAUD, B. GICQUEL, N. WINTER and C. LECLERC (*Equal contribution). Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J. Immunol., 2002, 168, 1294-1301.
G. DADAGLIO, C.M. SUN, R. LO-MAN, C.A. SIEGRIST and C. LECLERC. Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J. Immunol., 2002, 168, 2219-2224.
P. GUERMONPREZ, C. FAYOLLE, M.J. ROJAS, M. RESCIGNO, D. LADANT and C. LECLERC. In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c+CD8a-CD11bhigh dendritic cells. Eur. J. Immunol., 2002, 32, 3071-3081.
J. LOUCKA, G. SCHLECHT, J. VODOLANOVA, C. LECLERC and P. SEBO. Delivery of MalE CD4+ T cell epitope into MHC class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect. Immun., 2002, 70, 1002-1005.
M.K. GHOSH, E. DERIAUD, M.F. SARON, R. LO-MAN, T. HENRY, X. JIAO, P. ROY and C. LECLERC. Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. Vaccine, 2002, 20, 1369-1377.
M.K. GHOSH, C. LI, C. FAYOLLE, G. DADAGLIO, F. LEMONNIER, P. ROY and C. LECLERC. Induction of HLA-A2 restricted CTL responses by a tubular structure carrying human melanoma epitopes. Vaccine, 2002, 20, 2463-2473.
M. EL-AZAMI EL-IDRISSI, D. LADANT and C. LECLERC. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon, 2002, 40, 1661-1665.
F. BOISGERAULT, G. MORON and C. LECLERC. Virus-like particles: a new family of delivery systems. Expert Review of Vaccines, 2002, 1, 101-109.
P. MOINGEON and C. LECLERC. Vaccines of the future: from rational design to clinical development. Trends in Immunol., 2002, 23, 173-175.


P. GUERMONPREZ, N. KHELEF, E. BLOUIN, P. RIEU, P. RICCIARDI-CASTAGNOLI, N. GUISO, D. LADANT and C. LECLERC. The adenylate cylase toxin of Bordetella pertussis binds to target cells via the aMß2 integrin (CD11b/CD18). J. Exp. Med., 2001, 193, 1035-1044.
R. LO-MAN, S. VICHIER-GUERRE, S. BAY, E. DERIAUD, D. CANTACUZENE and C. LECLERC. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a Tri-Tn glycotope. J. Immunol., 2001, 166, 2849-2854.
G. SCHLECHT, C. LECLERC and G. DADAGLIO. Induction of CTL and non-polarized T helper responses by CD8a+ and CD8a- dendritic cells. J. Immunol., 2001, 167, 4215-4221.
C. FAYOLLE, A. OSICKOVA, R. OSICKA, T. HENRY, M.J. ROJAS, M.F. SARON, P. SEBO and C. LECLERC. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective anti-viral immunit. J. Virol., 2001, 75, 7330-7338.
P. RUEDA, G. MORON, J. SARRASECA, C. LECLERC and J.I. CASAL. Influence of flanking sequences on the processing and presentation of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles. J. Gen. Virol., 2004, 85, 563-572.
C. FAYOLLE, C. BAUCHE, D. LADANT and C. LECLERC. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8+ T-cell epitopes to dendritic cells in vivo. Vaccine, 2004, 23, 604-614.
S. VICHIER-GUERRE, R. LO-MAN, V. HUTEAU, E. DERIAUD, C. LECLERC and S. BAY. Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn-antigene. Bioorg Med Chem Lett. , 2004, 14, 3567-3570.